Trial Profile
A Phase 1 Clinical Trial to Evaluate Safety and to Compare the Immunogenicity of 3 DNA Vaccine Prime Schedules Followed by a NYVAC Vaccine Boost in Healthy, HIV-1 Uninfected Adult Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV DNA vaccine (Primary) ; NYVAC-C
- Indications HIV infections; HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 01 May 2018 Status changed from recruiting to active, no longer recruiting
- 12 Jun 2013 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
- 07 May 2013 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.